<DOC>
	<DOCNO>NCT01515241</DOCNO>
	<brief_summary>Despite availability several class effective drug available treat heterozygous Familial Hypercholesterolemia ( HeFH ) , remain large unmet medical need new , effective well tolerated therapy . There number therapy give chronic basis reduce long term risk , statin , fibrates , niacin , omega 3 fatty acid , resin , cholesterol absorption inhibitor antiplatelet anticoagulant drug , subject heterozygous Familial Hypercholesterolemia remain high risk cardiovascular event . There still need acute therapy lead rapid pacification unstable plaque order reduce risk event . This study assess effect CER-001 , recombinant human Apo-A-1 base HDL mimetic , index atherosclerotic plaque progression regression assess 3Tesla MRI ( 3TMRI ) intravascular ultrasound ( IVUS ) evaluations patient HeFH .</brief_summary>
	<brief_title>Exploratory Study Plaque Regression</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<criteria>Male Female subject least 18 year old Subject present heterozygous FH , know CHD receive maximally tolerate lipid modifying therapy , stable dos least 3 month LDLC &gt; 110 mg/dl Angiographic evidence coronary artery disease suitable `` target '' coronary artery IVUS Confirmed diagnosis homozygous FH Significant health problem ( cardiovascular disease ) recent past include blood disorder , cancer , digestive problem Female subject meet study definition non childbearing potential Use investigational agent within 30 day first CER001 dose Receiving current lipid apheresis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Heterozygous Familial Hypercholesterolemia</keyword>
	<keyword>Familial Hypercholesterolemia</keyword>
	<keyword>HDL mimetic</keyword>
	<keyword>ApoA-1</keyword>
</DOC>